Johnson & Johnson (JNJ) has been upgraded from Hold to Buy due to its consistent performance, stable revenue growth, and defensive qualities. The stock trades at a 20x forward P/E, reflecting a justified premium over peers supported by above-industry margins and accelerating revenue growth. The company benefits from its presence in the growing MedTech market, which could drive further valuation gains if earnings growth accelerates. Additionally, JNJ offers a 2.35% dividend yield, a strong capital structure, and serves as a diversification hedge against AI-related risks, making it attractive for long-term investors.
Johnson & Johnson has increased its quarterly dividend by 3.1%, marking 64 consecutive years of dividend growth. The company’s strong cash flow, with nearly double coverage of its dividend payout, and accelerating revenue growth of 9.9% in Q1 2026 su...
The SNPD ETF targets companies with at least 10 years of consecutive dividend growth, blending established Dividend Kings with promising newer payers. Its top holdings include Johnson & Johnson, Procter & Gamble, Coca-Cola, Lowe’s, and PepsiCo, most ...
Johnson & Johnson, McDonald's, and Kinder Morgan stand out as reliable dividend growers heading into late 2026. Johnson & Johnson raised its dividend for the 64th consecutive year, backed by strong revenue and earnings growth driven by oncology produ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Johnson & Johnson is distinguished by its steady growth, deep portfolio, and resilience, setting it apart from AI-driven and other pharma peers. The company’s diversified pharma and MedTech assets support robust revenue growth, with 28 platforms gene...
